To assess the function of fast somatic nerve fibers and sympathetic sudomotor system in patients with partial or generalized seizures, receiving various therapeutic regimes. The authors studied 60 patients (mean age 36.7 Ϯ 12.5 years) and 60 matched healthy controls by clinical, conventional nerve conduction study, and sympathetic skin responses (SSR) from hand and foot. Compared with controls, patients showed a tendency, occasional reaching significant level, to conduction slowing and amplitude reduction in the sensory and less often in the motor nerve study. Clinical signs of neuropathy were disclosed in 8.3% of patients, whereas at least one abnormal sensory parameter was evident in 18.3%. Mean SSR latencies in the patients were significantly prolonged. At least one SSR abnormality was shown in 20 (33.3%) patients; six of these had absent SSR from the hand or/and the foot. Polytherapy (vs. monotherapy) and topiramate, but not any other particular drug, seemed to have a negative effect on SSR measurements. The results suggested that despite the insignificant clinical manifestations of neuropathy, an electrophysiological examination was able to demonstrate some subclinical abnormalities of the fast somatic fibers in the peripheral nerves and of the sympathetic sudomotor function in a considerable number of epileptic patients.
T he question as to whether epilepsy could influence autonomic central drive, either during ictal discharges or as a result of epilepsy induced neuroplasticity has been repeatedly addressed. The majority of relevant studies focused on autonomic cardiovascular control and they were able to demonstrate derangement of sympathetic or/and parasympathetic activity, which could, at least theoretically, lead to arrhythmia and sudden death (Evrengül et al., 2005; Sathyaprabha et al., 2006; Tomson et al., 1998) . Moreover, antiepileptic medications, administrated usually for many years, have been also implicated in autonomic nervous system (ANS) alterations (Isojärvi et al., 1998) .
Exploration of possible effects of either epilepsy disorder or antiepileptic medications on peripheral nerves and sudomotor function is limited. Like other ANS functions, sympathetic medicated sweating is centrally regulated. This fact makes this activity vulnerable to changes of certain brain structures, such as hippocampus and limbic lobe. The possible relation between peripheral nerve function and epilepsy, a disease of central nervous system, is less obvious. However, noticeable abnormalities of conventional nerve conduction studies in epileptic patients have been previously reported and were mainly attributed to the effects of antiepileptic medications (Geraldini et al., 1984) . The aim of the current study was to assess the conduction properties of the fast somatic nerve fibers and the sympathetic sudomotor function in epileptic patients, taking into consideration factors related to clinical aspects of epilepsy and the antiepileptic medications.
MATERIALS AND METHODS

Subjects
Sixty patients were consecutively recruited from the Outpatients Epileptic Clinic of our Institution if they were diagnosed with epilepsy for no less than 6 months and were under the same therapeutic regimen for the last 6 months. Data on features of epilepsy were gathered from medical files, which include EEG recordings and neuroimaging studies. Sixty, age and sex-matched healthy subjects served as controls. All participants were free of any medication, that is, statins, known to affect autonomic or peripheral nerve function. Patients with diabetes mellitus, alcoholism, hepatic or renal disease or history of hereditary neuropathy were excluded. Individuals to whom magnetic stimulation is contraindicated because of metal prosthesis, pacemaker, etc. were also excluded. The study was approved by the institutional review board and signed informed consent was obtained from all examined subjects.
Experimental Protocol
Before testing, all patients were questioned about symptoms of sweating disturbances, motor or sensory dysfunction. Subsequently, they all underwent a detailed clinical examination aiming to detect any possible signs of autonomic or peripheral nerve disorder. The neurophysiological study, which followed, was carried-out for all participants in an air-conditioned, quiet room during the morning session (11.00 -13.00 hours). A two-chanell Counterpoint, MedtronicDandec apparatus (Medtronic-Dandec Electronics, Sakovlunde, Denmark) was used. The subjects, who were instructed not to consume nicotine, alcohol or caffeine on the examination day, were lay supine and the skin temperature of the examined limbs was maintained at 33°C Ϯ 0.5°C. All studies were performed unilaterally (right limbs) by the same investigator (V.S.), employing standard methods and my means of surface stimulation and recording electrodes (Kimura, 2001) . The electrophysiological evaluations were confirmed by an independent senior neurologist who checked both the recordings and results.
Neurophysiological Parameters
The neurophysiological profile consisted of (1) motor conduction of peroneal nerve with measurements of peak to baseline amplitude of compound muscle action potential, distal motor latency and motor conduction velocity; (2) Sensory conduction of ulnar (orthodromic technique) and sural nerve (antidromic technique) with measurements of peak-topeak amplitude of sensory action potential and sensory conduction velocity; (3) Sympathetic skin responses (SSR) was recorded from midpalm and referenced to dorsal hand surface using two types of stimulation: electrical stimulus of the ispilateral median nerve at the wrist, followed after an adequate interval by magnetic stimulation of cervical spinal cord by means of a circular coil placed in the midline over the seventh cervical spinous process; (4) SSR recorded from the sole (referenced to dorsal foot surface) to electrical stimulation of the tibial nerve at the ankle followed by magnetic stimulation of the lumbar region with the magnetic coil targeting the fifth lumbar spinous process. The SSR protocol applied in our laboratory has previously been standardized in healthy subjects (Chroni et al., 2006; Argyriou et al., 2006) . Three consecutive trials to each stimulus type were recorded in each subject and the response with the shorter latency was analyzed by measuring the onset latency, peak-to-peak amplitude and the area under the SSR curve.
Limits for identification of abnormality of individual measurements in the standard nerve conduction were set at: 7 V amplitude of sensory action potential for ulnar and sural nerve and 45 m/s and 42 m/s sensory conduction velocity for ulnar and sural nerve, respectively. In the motor conduction study of common peroneal nerve cut-off values were set at 1.5 mV for the amplitude of compound muscle action potential, 5.0 milliseconds for distal motor latency and 41 m/s for the motor conduction velocity. The 95% confidence limits for SSR parameters, employed for abnormality limits, were determined as mean Ϯ 2 SD of the healthy control group.
Statistics
Data were expressed as mean Ϯ SD. For comparison between patients and controls the nonparametric Mann-Whitney, two-tailed test for independent samples was applied. The association between categorical variables was studied by 2 test. Statistical significance was set at P Ͼ 0.05. All analyses were performed using SPSS for Window (10.0; SPSS Inc., Chicago, IL).
RESULTS
There were 28 men and 32 women age ranging from 18 to 63 years (mean age Ϯ SD 36.7 Ϯ 12.5 years). Four suffered simple partial seizures, 21 had complex partial, 22 had partial with secondary generalization, and 13 had idiopathic generalized tonic-clonic seizures. On average the monthly frequency was 10 or more seizures in 10 patients, between 2 and 9 in 11 patients and 0 and 1 seizure in 39 patients; 43 patients had at least one attack during the year before the examination. Age at onset of epilepsy was 21.4 Ϯ 13.6 years (ranging from 1 to 59 years) and duration of epilepsy was 15.4 Ϯ 12.2 years (ranging from 6 months to 48 years). At the time of the study, all patients were under antiepileptic medication. Thirty-six were under monotherapy and 24 were treated with various drug combinations. Carbamazepine was the only or part of the therapeutic regimen in 16 patients, valproate sodium, oxcarbazepine and lamotrigine in 14 patients each, levetiracetam in 10, topiramate in 9, phenytoin in 7, and phenobarbital in 5 patients.
As concerning features not directly related to the epilepsy itself, 5 patients characterized their hands as being most of the times cold-moist, 18 as warm-moist, 15 cold-dry, and 22 warm-dry. Eight patients described numbness or burning sensation in the distal limbs and in five of them (8.3% of all patients) the neurologic examination revealed suppressed ankle reflexes and reduced pain and /or vibration sense in lower or lower and upper limbs distally. Pyramidal signs due to structural brain lesion were present unilaterally in two patients.
The results of conventional motor and sensory conduction studies are presented in Table 1 . In the patients, as opposed to the controls, the study of peroneal nerve motor conduction showed a significant reduction of the mean amplitude of compound muscle action potential and prolongation of its distal motor latency. However, no individual measurement of motor conduction felt outside normal limits. In the sensory conduction study, significant slowing of mean ulnar sensory conduction velocity and reduction of mean amplitude of sural sensory action potential was found in the patients, as opposed to controls. Analysis of individual measurement showed that in four of the five patients the clinical signs of neuropathy were confirmed by electrophysiogical findings of reduced amplitude of the ulnar and/or sural sensory action potentials. Overall, 11 patients (18.3%) had abnormal value for at least one parameter of sensory conduction. The results of SSR study are given in Table 2 . There was a latency prolongation of SSR recorded in hand and foot to both types of stimulation in the patient as opposed to the control group. No difference of SSR amplitude or area between groups was noted.
SSR were absent from the hand in two patients and from the foot in five patients (Table 3 ). All but one of these six patients had partial seizure with or without secondary generalization and they were on polytherapy. The hands of all six patients were dry. When SSR to electrical stimulus were absent, were also unobtainable to magnetic stimulus and vise versa.
Based on the control group values the upper confidence limit for SSR latency at the hand to electrical stimulation was set at 2.09 seconds and to magnetic at 1.94 seconds. Likewise, the upper confidence limit for SSR latency at the foot to electrical stimulation was set at 2.45 seconds and to magnetic at 2.85 seconds. According to the above limits, evaluation of values of individual patients showed that in addition to the patients who had absent SSRs, 5 patients (8.3%) had prolonged latency in the hand SSR and 10 patients (16.6%) had prolonged latencies in the foot SSRs. Overall, 33.3% of the patients showed at least one abnormal SSR (absent or of prolonged latency). Because of great variability of amplitude and area values in the control group (high value of SD) confidence limits were not calculated for these parameters.
Chi-square analysis showed that the type of seizures was not associated with the presence of symptoms or clinical signs of neuropathy (P Ͼ 0.6). Likewise, seizure type was not related to the presence of abnormality in nerve conduction study (NCS) or SSR (P Ͼ 0.19). There were significantly more patients with normal SSR values in the subgroup of patients on monotherapy (28 of 36) as opposed to those on polytherapy (12 of 24 patients, P ϭ 0.049). There was no significant effect of any particular drug usage on the occurrence of NCS or SSR abnormalities with two exceptions: the 14 patients with lamotrigine in their therapeutic regimen had all SSR parameters normal values, whereas the subgroup of nine patients on topiramate showed higher percentage of SSR abnormalities (six patients). However, the SSR latency measurements remained significantly different (Ͻ0.05) between patients and controls even after exclusion of patients on topiramate (data not shown).
The subgroup of patients with relative controlled epilepsy (monthly seizure frequency 0 -3, n ϭ 50) showed no significantly less neurophysiological abnormalities than those (n ϭ 10) with higher seizure frequency (for NCS parameters P ϭ 0.371 and for SSR parameters P ϭ 0.279). Patients with epilepsy duration from 6 months to 10 years (n ϭ 25) showed no difference in NCS or SSR abnormalities as opposed to those (n ϭ 35) with longer duration (P ϭ 0.748 and P ϭ 0.096, respectively). The age of epilepsy onset (i.e., before the 25th year of age in 41 patients compared with the remaining 19 with late onset) was not correlated with SSR abnormalities (P ϭ 0.772).
However, significantly more abnormalities of NCS parameters were found in the latter subgroup (8 of 19 patients had at least one abnormal parameter versus 3 of 41 in the early onset subgroup, P ϭ 0.003). It should be noted that there was a statistical significant age difference at the time of the study between the two subgroups: mean age of the 41 
DISCUSSION
Estimation of functional status of somatic fibers in peripheral nerves and sympathetically controlled sweating in patients with epilepsy bears clinical and scientific interest. The potential long-term effects of epilepsy or antiepileptic medication on different nervous systems could have an additional impact on the quality of patients' life by causing disabling neuropathy or severe hyper/hypohidroris. Epilepsy is characterized by recurrent ictal events that could gradually modify the physiology and the anatomy of several brain regions, including hypothalamus, hippocampal formation and limbic lobe which are regarded as the principal loci of autonomic integration. It is therefore reasonable to examine whether the function of sweating is related to various parameters of epilepsy, including disease duration, type and frequency of seizures, type and duration of antiepileptic regimes. However, animal studies have proved that the action of certain antiepileptic medication is not restricted to the central nervous system, being able to influence dorsal root sensory ganglia and their distal connections (Connors, 1981) . Moreover, sural nerve biopsy in individual patients on antiepileptic therapy disclosed the presence of axonal degeneration with secondary myelin changes of nerve fibers (Bono et al., 1993) .
Several previous studies on epileptic patients have reported nerve conduction abnormalities, suggesting clinical or subclinical somatic fiber neuropathy. The incidence of these findings, as presented in Table 4 , varies considerably between studies, mainly depend on the particular drug used, duration of therapy and methodological issues of neurophysiological examination. Generally, sensory conduction was more frequent abnormal than motor (Martinez Figueroa et al., 1980; Shorvon and Reynolds, 1982; Bono et al., 1993) . The percentage of clinical signs of neuropathy, that is, suppressed ankle tendon reflexes and reduced pain sense in a stocking distribution, seems to be lower than that of electrophysiological abnormalities (Table 4 ).
In the current study, which is the first one that included patients treated with new antiepileptic medications, the frequency of somatic nerve fibers dysfunction was close to the modest estimations of the existing literature, which referred mainly to patients receiving first-generation antiepileptics. Individual analysis of our data showed that a percentage of 8.3% had neuropathy clinically and 18.3% had abnormal measurements of at least one neurophysiological parameter. More importantly, group analysis revealed that patients compared with controls demonstrated a tendency to conduction slowing and amplitude reduction reaching for several parameters significant level. The previously suggested potential higher risk for NCS abnormalities in elderly people with epilepsy (Bono et al., 1993) was confirmed by our results.
The etiology of these findings should be sought at the primary disorder, that is, epilepsy, or the antiepileptic medication. The first possibility is unlikely because it has been showed both in this study and previous ones that seizure type or frequency had no influence on peripheral nerves abnormalities. On the whole, there are no evidences from human or animal studies that long-term epileptic disorder, itself, could modify the function of peripheral nerves. Ideally, to exclude this possibility, it is required comparison between treated and drug-naive patients. However, this approach is not possible because of ethical restrictions. As a general consensus, nerve conduction changes in chronically treated patients has been attributed to the first generation antiepileptic drugs, that is, phenytoin, phenobarbital and to a lesser extent to carbamazepine (Danner et al., 1981 (Danner et al., , 1988 Shorvon and Reynolds, 1982; Geraldini et al., 1984) . In the present study, abnormalities similar to those previously reported were evidenced, despite the fact that treatment regimes of our patients included a wide variety of newer drugs. Keeping in mind the limitations concerning the small sample size for each particular drug and the fact that many patients were under multiple drug combinations, no drug seemed to be particularly related to the clinical or conventional nerve conduction findings. This observation is in good agreement with the previously expressed opinion that among carbamazepine, phenobarbital and phenytoin no drug has specific influence on neurophysiological data compared with the other two (Geraldini et al., 1984) .
The possibility of antiepileptic medication held responsibility for peripheral nerve damage is dictated by their biochemical activities. Although their action on peripheral nervous system has not been systematically researched, animal and human studies have suggested several possible mechanisms. The majority of antiepileptic drugs is considered capable of decreasing neuronal membrane excitability by blockage of voltage-dependent sodium and potassium conductance, particularly in the vicinity of node of Ranvier (VanDongen et al., 1986; Yates et al., 2005) . The result would be an increase of firing threshold, slowing of conduction velocity and even block of potential propagation through affected regions (Guven et al., 2006) . Other mechanisms, such as enhancement of GABA-ergic inhibition or alteration of glutaminergic and serotonergic functions may also contribute to the effects of antiepileptic medications on peripheral nervous system (VanDongen et al., 1986; Kudoh and Matsuki, 2000) . Alternatively, antiepileptic drug-induced deficiency of essential molecules, such as folic acid, might caused peripheral nerve damage (Martinez Figueroa et al., 1980; Shorvon and Reynolds, 1982) . Further support on these drug effects is provided by an experimental study on 60 rats, which received a 6-month phenytoin treatment and showed preferential involvement of sensory as opposed to motor fibers, confirmed by histologic evidences of myelinated fibers changes (Moglia et al., 1981) .
SSR is a simple, accessible index of sudomotor sympathetic function, reflecting changes of central autonomic control and efferent pathways subserving sweating. SSR is a slow potential change in the electrical conductance of the skin generated by various internal (i.e., deep breathing) and external stimuli (Arunodaya and Taly 1995) . The reason for applying both electrical and magnetic stimulation in the present study was to eliminate false positive findings, which would result from an incidental failure of one type of stimulation to elicit a response. Studies aiming to assess sweating function in patients with epilepsy are limited.
In our material the mean latency of SSR elicited by electrical and magnetic stimulation in both hands and feet were significantly increased in the epileptic group compared with controls. When individual measurements were considered one third of the patient population has, at least one, SSR latency outside normal limits. There was no significant difference of SSR amplitude and area between patients and controls. The latter was not an unexpected finding because these parameters are generally considered as less reliable because of their large variability even in healthy control population (Shahani et al., 1990) . Finally, we found no evidence to suggest a relationship between occurrence of SSR abnormalities and conventional nerve conduction changes. In agreement with our analysis of SSR measurements, a study including 50 treated and untreated patients with various epilepsies showed an overall mean SSR latency increase in the patients as opposed to the healthy controls (Drake et al., 1998) . In another study of nine untreated patients with partial epilepsy the SSR latency found to be prolonged, which, however, return to normal after treatment initiation (Berilgen et al., 2004) .
There is no an obvious explanation for these SSR changes in our patients. Sweating dysfunction confirmed by impaired SSR has been reported in central nervous system diseases, such as stroke and extrapyramidal syndromes (Vetrugno et al., 2003) . Cardiovascular autonomic regulation seemed to be impaired in patients with epilepsy, especially that of temporal lobe (Tomson et al., 1998) . It is conceivable that direct or indirect, via connections, involvement of ANS brain centers in the generation and spreading of epileptiform discharges could result in SSR abnormalities. However, in analogy to the study of peripheral nerve function, we were not able to detect any difference of the frequency of SSR abnormalities among subgroups with different types of epilepsy (i.e., between patients with generalized and those with partial epilepsies). It is no easy to distinguish between the effects on ANS function of epilepsy as such from those of the antiepileptic medication. Most studies suggested that both possibilities are contributing to the ANS changes (Tomson et al., 1998; Drake et al., 1998) .
The probability that antiepileptic medications or any particular drug could influence SSR measurements should also be considered. In the present study, topiramate was the only drug that was significantly associated with SSR abnormalities. However, our findings showed that topiramate therapy alone could not hold exclusively responsible for SSR differences between epileptic patients and controls. Topiramate-induced hyperhidrosis, reversible after drug discontinuation, has been noted in few cases (Cerminara et al., 2006) . It has been suggested that topiramate could cause changes at sweat glands, possibly through inhibition of carbonic anhydrase isoenzymes II and IV being localized in human eccrine sweat glands (de Carolis et al., 2003; Cerminara et al., 2006) . The potential role of drugs on sympathetic sudomotor function was also implied by our finding that patients on multiple drug regimes are more likely to develop SSR abnormalities than those on monotherapy. We acknowledge the limitation of this study not to record the exact duration of current treatment, although it remained unchanged during the last 6 months before the study. In many patients, antiepileptic therapy had been modified several times over the years as new drugs were introduced. Hence, the potential influence of previous regimes on the nerve function and SSR measurements can not be estimated.
In conclusion, the systematic electrophysiological examination of patients with different types of epilepsy under treatment with various therapeutic regimes revealed some abnormalities of conduction of the fast somatic fibers in peripheral nerves and more so of the sympathetic sudomotor function. It should be noted that symptoms and clinical signs of neuropathy or complains of sweating disturbances were infrequent or insignificant in our patients, implying that the observed changes do not seem to have a major impact on their quality of life. The mechanisms underlying slowing of conduction or delayed SSR is not apparent. At present, particularly for the SSR changes a multifactorial etiology seems more likely.
